

Title (en)

MODIFIED TRANSFERRIN FUSION PROTEINS

Title (de)

MODIFIZIERTE TRANSFERRINFUSIONSPROTEINE

Title (fr)

PROTEINES HYBRIDES MODIFIEES DE TRANSFERRINE

Publication

EP 1858546 A4 20090304 (EN)

Application

EP 06736868 A 20060306

Priority

- US 2006007617 W 20060306
- US 65814005 P 20050304
- US 66375705 P 20050322

Abstract (en)

[origin: WO2006096515A2] Modified fusion proteins of a transferrin moiety, a GLP-1 moiety and a linker moiety, with increased productivity, bioactivity and serum half-life are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation. The fusion proteins of the invention are useful for the treatment of Type 2 diabetes, Type 1 diabetes, obesity, congestive heart failure, and non-fatty liver disease.

IPC 8 full level

C12N 15/12 (2006.01); **A61K 38/26** (2006.01); **A61K 38/40** (2006.01); **C07K 14/605** (2006.01); **C07K 14/76** (2006.01); **C12N 5/10** (2006.01); **C12N 15/16** (2006.01); **C12N 15/63** (2006.01); **C12P 21/02** (2006.01)

CPC (source: EP)

A61K 38/26 (2013.01); **A61K 47/644** (2017.07); **A61P 1/16** (2017.12); **A61P 3/04** (2017.12); **A61P 3/10** (2017.12); **A61P 5/50** (2017.12); **A61P 9/04** (2017.12); **A61P 43/00** (2017.12); **C07K 14/605** (2013.01); **C07K 14/79** (2013.01); **C07K 2319/00** (2013.01)

Citation (search report)

- [PX] WO 2006017688 A2 20060216 - BIOREXIS PHARMACEUTICAL CORP [US], et al
- [A] US 5545618 A 19960813 - BUCKLEY DOUGLAS I [US], et al
- See references of WO 2006096515A2

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2006096515 A2 20060914; **WO 2006096515 A3 20061207**; CA 2599723 A1 20060914; EP 1858546 A2 20071128; EP 1858546 A4 20090304; JP 2008531059 A 20080814

DOCDB simple family (application)

US 2006007617 W 20060306; CA 2599723 A 20060306; EP 06736868 A 20060306; JP 2007558273 A 20060306